JUL 07, 2020 11:00 AM PDT

Comprehensive landscape of the tumor microenvironment analyzed with CyTOF® technology

Speaker
  • Professor, National Cancer Center, Japan
    Biography
      Professor Hiroyoshi Nishikawa is Division Chief of Cancer Immunology at the Research Institute/Exploratory Oncology Research & Clinical Trial Center (EPOC) at the National Cancer Center Japan and a Professor of Immunology at Nagoya University Graduate School of Medicine. Throughout his career his research has focused on tumor biology, tumor therapeutics and immunology. Currently his group aims to comprehensively investigate immune cells such as CD4+, CD8+ T cells and macrophages, cancer cells and environmental factors to clarify the molecular mechanisms that control immune balances in a tumor microenvironment. Nishikawa is an author of two books, Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies and Regulatory T Cells, in addition to numerous research publications.

      Nishikawa completed his medical and PhD graduate degree from Mie University. He was a research fellow at the Memorial Sloan Kettering Cancer Center and in 2012 took a position as Adjunctive Associate Professor at the Roswell Park Comprehensive Cancer Center.

    Abstract

    Immune escape mechanisms such as the induction/recruitment of immunosuppressive cells and the increased expression of various immunosuppressive molecules including PD-1/PD-1 ligands are essential processes during cancer development and progression, leading to the development of complex immune-suppressive networks in the tumor microenvironment. Thus, high-dimensional immune profiling using CyTOF® technology for single-cell phenotype and function analysis plays an important role to develop more effective cancer immunotherapeutic strategies and to define biomarkers for stratifying responders and non-responders via the detailed analysis of immune responses in cancer patients.

    Fluidigm products are for research only. Not for use in diagnostic procedures.


    Show Resources
    You May Also Like
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    MAR 18, 2021 8:00 AM PDT
    C.E. CREDITS
    MAR 18, 2021 8:00 AM PDT
    DATE: March 18, 2021 TIME: 8:00am PDT Sequencing of bulk cells, single cells, and nuclei is opening doors in the understanding of complex biological processes....
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    Loading Comments...
    Show Resources
    Attendees
    • See more